慢性阻塞性肺疾病并發侵襲性肺曲霉病診治策略_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

葉先平 , 朱美英 , 劉璐璐 , 陳碧琳 , 施毅 ,  蘇欣

南京醫科大學金陵臨床醫學院（解放軍南京總醫院）呼吸與危重癥醫學科（江蘇南京 210002）;

Corresponding?author：

蘇欣, Email: suxinjs@163.com

Keywords：

DOI：

10.7507/1671-6205.201802021

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 葉先平, 朱美英, 劉璐璐, 陳碧琳, 施毅, 蘇欣. 慢性阻塞性肺疾病并發侵襲性肺曲霉病診治策略. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(4): 392-395. doi: 10.7507/1671-6205.201802021 Copy

1.	Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax, 2015, 70: 270-277.
2.	Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev, 2009, 22(3): 447-465.
3.	Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis. 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2016, 63(4): e1-e60.
4.	江浩, 趙蓓蕾, 施毅, 等. 侵襲性肺曲霉病 20 例. 中國感染與化療雜志, 2009, 9(4): 293-296.
5.	Denning DW. The ambitious ‘95-95 by 2025’ roadmap for the diagnosis and management of fungal diseases. Thorax, 2015, 70(7): 613-614.
6.	Huang LN, He HY, Jin JJ, et al. Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/MSG and ICU criteria. BMC Infect Dis, 2017, 17(1): 209.
7.	Russo A, Falcone M, Vena A, et al. Invasive pulmonary aspergillosis in non-neutropenic patients. Analysis of a 14-month prospective clinical experience. J Chemother, 2011, 23(5): 290-294.
8.	Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease. An emerging fungal pathogen. Clin Microbiol Infect, 2005, 11(6): 427-429.
9.	Xia D, Sun WK, Tan MM, et al. An adenoviral vector encoding full-length dectin-1 promotes Aspergillus-induced innate immune response in macrophages. Lung, 2015, 193(4): 549-557.
10.	Liu C, Wang M, Sun W, et al. PU.1 serves a critical role in the innate defense against Aspergillus fumigatus via dendritic cell-associated C-type lectin receptor-1 and toll-like receptors-2 and 4 in THP-1-derived macrophages. Mol Med Rep, 2017, 15(6): 4084-4092.
11.	Wang M, Liu ZC, Liu CY, et al. PU.1 is involved in the immune response to Aspergillus fumigatus through upregulating Dectin-1 expression. BMC Infect Dis, 2016, 16: 297.
12.	Sun H, Xu XY, Shao HT, et al. Dectin-2 is predominately macrophage restricted and exhibits conspicuous expression during Aspergillus fumigatus invasion in human lung. Cell Immunol, 2013, 284(1-2): 60-67.
13.	Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med, 2014, 370(5): 421-432.
14.	He Q, Li HX, Rui YW, et al. Pentraxin 3 gene polymorphisms and pulmonary aspergillosis in chronic obstructive pulmonary disease patients. Clin Infect Dis, 2018, 66(2): 261-267.
15.	Liang S, Jiang R, Lu HW, et al. Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults. J Thorac Dis, 2017, 9(2): 247-253.
16.	Patel DA, Gao X, Stephens JM, et al. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. J Med Econ, 2011, 14(2): 227-237.
17.	Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect, 2010, 16(7): 870-877.
18.	Xu H, Li L, Huang WJ, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. A case control study from China. Clin Microbiol Infect, 2012, 18(4): 403-408.
19.	Barberan J, Sanz F, Hernandez JL, et al. Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage. J Infect, 2012, 65(5): 447-452.
20.	Schelenz S, Barnes RA, Barton RC, et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis, 2015, 15(4): 461-474.
21.	Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med, 1996, 100(2): 171-178.
22.	Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis, 2011, 52(6): 750-770.
23.	Ku NS, Han SH, Choi JY, et al. Diagnostic value of the serum galactomannan assay for invasive aspergillosis. It is less useful in non-haematological patients. Scand J Infect Dis, 2012, 44(8): 600-604.
24.	De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008, 46(12): 1813-1821.
25.	Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol, 2017, 55(7): 2153-2161.
26.	Guitard J, Sendid B, Thorez S, et al. Evaluation of a recombinant antigen-based enzyme immunoassay for the diagnosis of noninvasive aspergillosis. J Clin Microbiol, 2012, 50(3): 762-765.
27.	Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis. Rationale and clinical guidelines for diagnosis and management. Eur Respir J, 2016, 47(1): 45-68.
28.	Du C, Wingard JR, Cheng S, et al. Serum IgG responses against Aspergillus proteins before hematopoietic stem cell transplantation or chemotherapy identify patients who develop invasive aspergillosis. Biol Blood Marrow Transplant, 2012, 18(12): 1927-1934.
29.	Page ID, Richardson M, Denning DW. Antibody testing in aspergillosis--quo vadis?. Med Mycol, 2015, 53(5): 417-439.
30.	Matthews R, Burnie JP, Fox A, et al. Immunoblot analysis of serological responses in invasive aspergillosis. J Clin Pathol, 1985, 38(11): 1300-1303.
31.	Kappe R, Rimek D. Antikorper-Nachweis bei invasiver Aspergillose. Mycoses, 2004, 47(Suppl 1): 55-59.
32.	Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients. A randomised controlled trial. Lancet Infect Dis, 2013, 13(6): 519-528.
33.	Barnes RA, White PL, Bygrave C, et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol, 2009, 62(1): 64-69.
34.	Ni PX, Ding X, Zhang YX, et al. Rapid detection and identification of infectious pathogens based on high-throughput sequencing. Chin Med J (Engl), 2015, 128(7): 877-883.
35.	Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med, 2013, 369(25): 2369-2371.
36.	Calistri A, Salata C, Parolin C, et al. New generation sequencing in pathogen discovery and microbial surveillance. Expert Rev Anti Infect Ther, 2013, 11(9): 877-879.
37.	Wilson MR, Naccache SN, Samayoa E, et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med, 2014, 370(25): 2408-2417.
38.	Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J, 2007, 30(4): 782-800.
39.	Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis, 2007, 44(8): 1078-1083.
40.	Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev, 2011, 24(2): 247-280.
41.	Nosari A, Anghilieri M, Carrafiello G, et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica, 2003, 88(12): 1405-1409.
42.	Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002, 34(1): 7-14.
43.	Blot SI, Taccone FS, van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med, 2012, 186(1): 56-64.
44.	Baddley JW, Stephens JM, Ji X, et al. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis, 2013, 13: 29.
45.	Bassetti M, Righi E, de Pascale G, et al. How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care, 2014, 18(4): 458.
46.	Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies. Are we there yet?. Br J Haematol, 2011, 153(6): 681-697.
47.	Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect, 2012, 18(Suppl 7): 19-37.
48.	Shi YQ, Li P, Wu T, et al. Integrated therapy for invasive pulmonary aspergillosis in a patient with asthma and chronic obstructive pulmonary disease overlap syndrome. Chin Med J (Engl), 2015, 128(16): 2265-2266.

1. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax, 2015, 70: 270-277.
2. Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev, 2009, 22(3): 447-465.
3. Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis. 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis, 2016, 63(4): e1-e60.
4. 江浩, 趙蓓蕾, 施毅, 等. 侵襲性肺曲霉病 20 例. 中國感染與化療雜志, 2009, 9(4): 293-296.
5. Denning DW. The ambitious ‘95-95 by 2025’ roadmap for the diagnosis and management of fungal diseases. Thorax, 2015, 70(7): 613-614.
6. Huang LN, He HY, Jin JJ, et al. Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease? A comparative study with EORTC/MSG and ICU criteria. BMC Infect Dis, 2017, 17(1): 209.
7. Russo A, Falcone M, Vena A, et al. Invasive pulmonary aspergillosis in non-neutropenic patients. Analysis of a 14-month prospective clinical experience. J Chemother, 2011, 23(5): 290-294.
8. Ader F, Nseir S, Le Berre R, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease. An emerging fungal pathogen. Clin Microbiol Infect, 2005, 11(6): 427-429.
9. Xia D, Sun WK, Tan MM, et al. An adenoviral vector encoding full-length dectin-1 promotes Aspergillus-induced innate immune response in macrophages. Lung, 2015, 193(4): 549-557.
10. Liu C, Wang M, Sun W, et al. PU.1 serves a critical role in the innate defense against Aspergillus fumigatus via dendritic cell-associated C-type lectin receptor-1 and toll-like receptors-2 and 4 in THP-1-derived macrophages. Mol Med Rep, 2017, 15(6): 4084-4092.
11. Wang M, Liu ZC, Liu CY, et al. PU.1 is involved in the immune response to Aspergillus fumigatus through upregulating Dectin-1 expression. BMC Infect Dis, 2016, 16: 297.
12. Sun H, Xu XY, Shao HT, et al. Dectin-2 is predominately macrophage restricted and exhibits conspicuous expression during Aspergillus fumigatus invasion in human lung. Cell Immunol, 2013, 284(1-2): 60-67.
13. Cunha C, Aversa F, Lacerda JF, et al. Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. N Engl J Med, 2014, 370(5): 421-432.
14. He Q, Li HX, Rui YW, et al. Pentraxin 3 gene polymorphisms and pulmonary aspergillosis in chronic obstructive pulmonary disease patients. Clin Infect Dis, 2018, 66(2): 261-267.
15. Liang S, Jiang R, Lu HW, et al. Immunity status of invasive pulmonary aspergillosis patients with structural lung diseases in Chinese adults. J Thorac Dis, 2017, 9(2): 247-253.
16. Patel DA, Gao X, Stephens JM, et al. US hospital database analysis of invasive aspergillosis in the chronic obstructive pulmonary disease non-traditional host. J Med Econ, 2011, 14(2): 227-237.
17. Guinea J, Torres-Narbona M, Gijón P, et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect, 2010, 16(7): 870-877.
18. Xu H, Li L, Huang WJ, et al. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. A case control study from China. Clin Microbiol Infect, 2012, 18(4): 403-408.
19. Barberan J, Sanz F, Hernandez JL, et al. Clinical features of invasive pulmonary aspergillosis vs. colonization in COPD patients distributed by gold stage. J Infect, 2012, 65(5): 447-452.
20. Schelenz S, Barnes RA, Barton RC, et al. British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases. Lancet Infect Dis, 2015, 15(4): 461-474.
21. Horvath JA, Dummer S. The use of respiratory-tract cultures in the diagnosis of invasive pulmonary aspergillosis. Am J Med, 1996, 100(2): 171-178.
22. Karageorgopoulos DE, Vouloumanou EK, Ntziora F, et al. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. Clin Infect Dis, 2011, 52(6): 750-770.
23. Ku NS, Han SH, Choi JY, et al. Diagnostic value of the serum galactomannan assay for invasive aspergillosis. It is less useful in non-haematological patients. Scand J Infect Dis, 2012, 44(8): 600-604.
24. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis, 2008, 46(12): 1813-1821.
25. Zhou W, Li H, Zhang Y, et al. Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol, 2017, 55(7): 2153-2161.
26. Guitard J, Sendid B, Thorez S, et al. Evaluation of a recombinant antigen-based enzyme immunoassay for the diagnosis of noninvasive aspergillosis. J Clin Microbiol, 2012, 50(3): 762-765.
27. Denning DW, Cadranel J, Beigelman-Aubry C, et al. Chronic pulmonary aspergillosis. Rationale and clinical guidelines for diagnosis and management. Eur Respir J, 2016, 47(1): 45-68.
28. Du C, Wingard JR, Cheng S, et al. Serum IgG responses against Aspergillus proteins before hematopoietic stem cell transplantation or chemotherapy identify patients who develop invasive aspergillosis. Biol Blood Marrow Transplant, 2012, 18(12): 1927-1934.
29. Page ID, Richardson M, Denning DW. Antibody testing in aspergillosis--quo vadis?. Med Mycol, 2015, 53(5): 417-439.
30. Matthews R, Burnie JP, Fox A, et al. Immunoblot analysis of serological responses in invasive aspergillosis. J Clin Pathol, 1985, 38(11): 1300-1303.
31. Kappe R, Rimek D. Antikorper-Nachweis bei invasiver Aspergillose. Mycoses, 2004, 47(Suppl 1): 55-59.
32. Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients. A randomised controlled trial. Lancet Infect Dis, 2013, 13(6): 519-528.
33. Barnes RA, White PL, Bygrave C, et al. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol, 2009, 62(1): 64-69.
34. Ni PX, Ding X, Zhang YX, et al. Rapid detection and identification of infectious pathogens based on high-throughput sequencing. Chin Med J (Engl), 2015, 128(7): 877-883.
35. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med, 2013, 369(25): 2369-2371.
36. Calistri A, Salata C, Parolin C, et al. New generation sequencing in pathogen discovery and microbial surveillance. Expert Rev Anti Infect Ther, 2013, 11(9): 877-879.
37. Wilson MR, Naccache SN, Samayoa E, et al. Actionable diagnosis of neuroleptospirosis by next-generation sequencing. N Engl J Med, 2014, 370(25): 2408-2417.
38. Bulpa P, Dive A, Sibille Y. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. Eur Respir J, 2007, 30(4): 782-800.
39. Rickerts V, Mousset S, Lambrecht E, et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis, 2007, 44(8): 1078-1083.
40. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev, 2011, 24(2): 247-280.
41. Nosari A, Anghilieri M, Carrafiello G, et al. Utility of percutaneous lung biopsy for diagnosing filamentous fungal infections in hematologic malignancies. Haematologica, 2003, 88(12): 1405-1409.
42. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis, 2002, 34(1): 7-14.
43. Blot SI, Taccone FS, van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med, 2012, 186(1): 56-64.
44. Baddley JW, Stephens JM, Ji X, et al. Aspergillosis in intensive care unit (ICU) patients: epidemiology and economic outcomes. BMC Infect Dis, 2013, 13: 29.
45. Bassetti M, Righi E, de Pascale G, et al. How to manage aspergillosis in non-neutropenic intensive care unit patients. Crit Care, 2014, 18(4): 458.
46. Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies. Are we there yet?. Br J Haematol, 2011, 153(6): 681-697.
47. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect, 2012, 18(Suppl 7): 19-37.
48. Shi YQ, Li P, Wu T, et al. Integrated therapy for invasive pulmonary aspergillosis in a patient with asthma and chronic obstructive pulmonary disease overlap syndrome. Chin Med J (Engl), 2015, 128(16): 2265-2266.

Previous Article
多組織學類型肺癌一例
Next Article
血嗜酸性粒細胞在慢性阻塞性肺疾病的臨床研究進展

Chinese Journal of Respiratory and Critical Care Medicine

慢性阻塞性肺疾病并發侵襲性肺曲霉病診治策略

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content